269 related articles for article (PubMed ID: 30816547)
1. Novel drug candidate for the treatment of several soft‑tissue sarcoma histologic subtypes: A computational method using survival‑associated gene signatures for drug repurposing.
Yang X; Huang WT; Wu HY; He RQ; Ma J; Liu AG; Chen G
Oncol Rep; 2019 Apr; 41(4):2241-2253. PubMed ID: 30816547
[TBL] [Abstract][Full Text] [Related]
2. Drug repositioning in head and neck squamous cell carcinoma: An integrated pathway analysis based on connectivity map and differential gene expression.
Wei GG; Gao L; Tang ZY; Lin P; Liang LB; Zeng JJ; Chen G; Zhang LC
Pathol Res Pract; 2019 Jun; 215(6):152378. PubMed ID: 30871913
[TBL] [Abstract][Full Text] [Related]
3. In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme.
Xiong DD; Xu WQ; He RQ; Dang YW; Chen G; Luo DZ
Oncol Rep; 2019 Apr; 41(4):2194-2208. PubMed ID: 30816530
[TBL] [Abstract][Full Text] [Related]
4. Novel drug candidates for treating esophageal carcinoma: A study on differentially expressed genes, using connectivity mapping and molecular docking.
Chen YT; Xie JY; Sun Q; Mo WJ
Int J Oncol; 2019 Jan; 54(1):152-166. PubMed ID: 30387840
[TBL] [Abstract][Full Text] [Related]
5. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.
Zador Z; King AT; Geifman N
PLoS One; 2018; 13(3):e0194701. PubMed ID: 29558515
[TBL] [Abstract][Full Text] [Related]
6. The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets.
Pang JS; Li ZK; Lin P; Wang XD; Chen G; Yan HB; Li SH
Oncol Rep; 2019 Apr; 41(4):2089-2102. PubMed ID: 30816528
[TBL] [Abstract][Full Text] [Related]
7. Survival analysis of genome-wide profiles coupled with Connectivity Map database mining to identify potential therapeutic targets for cholangiocarcinoma.
Lin P; Zhong XZ; Wang XD; Li JJ; Zhao RQ; He Y; Jiang YQ; Huang XW; Chen G; He Y; Yang H
Oncol Rep; 2018 Dec; 40(6):3189-3198. PubMed ID: 30272356
[TBL] [Abstract][Full Text] [Related]
8. Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma.
Zhu FX; He YC; Zhang JY; Wang HF; Zhong C; Wang XT
Med Sci Monit; 2019 May; 25():3247-3255. PubMed ID: 31048671
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma.
Xu S; Liu R; Da Y
Thorac Cancer; 2018 Aug; 9(8):974-988. PubMed ID: 29870138
[TBL] [Abstract][Full Text] [Related]
10. Integration of genetic variants and gene network for drug repurposing in colorectal cancer.
Irham LM; Wong HS; Chou WH; Adikusuma W; Mugiyanto E; Huang WC; Chang WC
Pharmacol Res; 2020 Nov; 161():105203. PubMed ID: 32950641
[TBL] [Abstract][Full Text] [Related]
11. Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database.
Luo B; Gu YY; Wang XD; Chen G; Peng ZG
Pathol Res Pract; 2018 Nov; 214(11):1854-1867. PubMed ID: 30244948
[TBL] [Abstract][Full Text] [Related]
12. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic Data Mining and Repurposing for Computational Drug Discovery.
Wang Y; Yella J; Jegga AG
Methods Mol Biol; 2019; 1903():73-95. PubMed ID: 30547437
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer.
Yu C; Hong H; Lu J; Zhao X; Hu W; Zhang S; Zong Y; Mao Z; Li J; Wang M; Feng B; Sun J; Zheng M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806905. PubMed ID: 30336768
[TBL] [Abstract][Full Text] [Related]
15. Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas.
van IJzendoorn DGP; Szuhai K; Briaire-de Bruijn IH; Kostine M; Kuijjer ML; Bovée JVMG
PLoS Comput Biol; 2019 Feb; 15(2):e1006826. PubMed ID: 30785874
[TBL] [Abstract][Full Text] [Related]
16. Molecular Network-Based Drug Prediction in Thyroid Cancer.
Xu X; Long H; Xi B; Ji B; Li Z; Dang Y; Jiang C; Yao Y; Yang J
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30641858
[TBL] [Abstract][Full Text] [Related]
17. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
18. [Histology-Specific Chemotherapy in Soft-Tissue Sarcomas].
Kobayashi E; Kawai A
Gan To Kagaku Ryoho; 2017 Jun; 44(6):468-472. PubMed ID: 28698435
[TBL] [Abstract][Full Text] [Related]
19. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures.
Lee H; Kang S; Kim W
PLoS One; 2016; 11(3):e0150460. PubMed ID: 26954019
[TBL] [Abstract][Full Text] [Related]
20. MNBDR: A Module Network Based Method for Drug Repositioning.
Chen HG; Zhou XH
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
